← Oncology Approval Tracker

FDA DECISION ·

Udenyca Onbody

pegfilgrastim-cbqv · Coherus BioSciences

FDA approvalNew formulationChemotherapy-associated neutropenia
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

An on-body injector presentation for Udenyca to lower infection risk from febrile neutropenia in qualifying patients with nonmyeloid malignancies receiving myelosuppressive anticancer therapy.

LAMPGEN ANALYSIS

Why it matters

The new delivery presentation can separate device placement from drug administration.

What research teams should watch

Train staff and patients on correct placement, delivery confirmation and management of device failure.

PRIMARY RECORDS

Sources